Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response
Understanding the efficacy and durability of heterologous immunization schedules against SARS-CoV-2 is critical, as supply demands and vaccine choices become significant issues in the global vaccination strategy. Here we characterize the neutralizing antibodies produced in two subjects who received...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2021-05-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/15368 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148836616437760 |
|---|---|
| author | Ali Toloue Ostadgavahi Ryan Booth Gary Sisson Nichole McMullen Michelle Warhuus Peter Robertson Matthew Miller Wanda C Allen May El Sherif Robert Brownlie Darryl Falzarano Christopher D Richardson |
| author_facet | Ali Toloue Ostadgavahi Ryan Booth Gary Sisson Nichole McMullen Michelle Warhuus Peter Robertson Matthew Miller Wanda C Allen May El Sherif Robert Brownlie Darryl Falzarano Christopher D Richardson |
| author_sort | Ali Toloue Ostadgavahi |
| collection | DOAJ |
| description |
Understanding the efficacy and durability of heterologous immunization schedules against SARS-CoV-2 is critical, as supply demands and vaccine choices become significant issues in the global vaccination strategy. Here we characterize the neutralizing antibodies produced in two subjects who received combination immunizations against SARS-CoV-2, first with Covishield (Oxford–AstraZeneca) vaccine, followed 33 days later with a second dose (booster) shot of the Pfizer-BioNTech vaccine. Serum samples were collected 25 days following the primary vaccination and 13 days after the secondary Pfizer vaccination. Both subjects exhibited increased levels of isotype IgG and IgM antibodies directed against the entire spike protein following immunizations. These antibodies also exhibited increased reactivity with the receptor binding domain (RBD) in the spike protein and neutralized the infectivity of replicating vesicular stomatitis virus (VSV) that contains the COVID-19 coronavirus S protein gene in place of its normal G glycoprotein. This VSV pseudovirus also contains the reporter gene for enhanced green fluorescent protein (eGFP). Antibody titers against the spike protein and serum neutralization titers against the reporter virus are reported for the 2 heterologous vaccinated individuals and compared to a positive control derived from a convalescent patient and a negative control from an unexposed individual. The Pfizer-BioNTech vaccine increased antibody binding to the spike protein and RBD, and approached levels found in the convalescent positive control. Neutralizing antibodies against the VSV-S pseudovirus in the 2 subjects also approached levels in the convalescent sera. These results firmly validate the value of the Pfizer-BioNTech vaccine in boosting immunity following initial Covishield inoculation.
|
| format | Article |
| id | doaj-art-f007d92369cc4aefbe94bf902bdaa901 |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2021-05-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-f007d92369cc4aefbe94bf902bdaa9012025-08-20T02:27:07ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802021-05-01150510.3855/jidc.15368Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune responseAli Toloue Ostadgavahi0Ryan Booth1Gary Sisson2Nichole McMullen3Michelle Warhuus4Peter Robertson5Matthew Miller6Wanda C Allen7May El Sherif8Robert Brownlie9Darryl Falzarano10Christopher D Richardson11Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, CanadaDepartment of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, CanadaDepartment of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, CanadaDepartment of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, CanadaCanadian Centre for Vaccinology, Dalhousie University, Halifax, Nova Scotia, CanadaCanadian Centre for Vaccinology, Dalhousie University, Halifax, Nova Scotia, CanadaCanadian Centre for Vaccinology, Dalhousie University, Halifax, Nova Scotia, CanadaCanadian Centre for Vaccinology, Dalhousie University, Halifax, Nova Scotia, CanadaCanadian Centre for Vaccinology, Dalhousie University, Halifax, Nova Scotia, CanadaVaccine and Infectious Disease Organization (VIDO), Saskatoon, Saskatchewan, CanadaVaccine and Infectious Disease Organization (VIDO), Saskatoon, Saskatchewan, CanadaDepartment of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada Understanding the efficacy and durability of heterologous immunization schedules against SARS-CoV-2 is critical, as supply demands and vaccine choices become significant issues in the global vaccination strategy. Here we characterize the neutralizing antibodies produced in two subjects who received combination immunizations against SARS-CoV-2, first with Covishield (Oxford–AstraZeneca) vaccine, followed 33 days later with a second dose (booster) shot of the Pfizer-BioNTech vaccine. Serum samples were collected 25 days following the primary vaccination and 13 days after the secondary Pfizer vaccination. Both subjects exhibited increased levels of isotype IgG and IgM antibodies directed against the entire spike protein following immunizations. These antibodies also exhibited increased reactivity with the receptor binding domain (RBD) in the spike protein and neutralized the infectivity of replicating vesicular stomatitis virus (VSV) that contains the COVID-19 coronavirus S protein gene in place of its normal G glycoprotein. This VSV pseudovirus also contains the reporter gene for enhanced green fluorescent protein (eGFP). Antibody titers against the spike protein and serum neutralization titers against the reporter virus are reported for the 2 heterologous vaccinated individuals and compared to a positive control derived from a convalescent patient and a negative control from an unexposed individual. The Pfizer-BioNTech vaccine increased antibody binding to the spike protein and RBD, and approached levels found in the convalescent positive control. Neutralizing antibodies against the VSV-S pseudovirus in the 2 subjects also approached levels in the convalescent sera. These results firmly validate the value of the Pfizer-BioNTech vaccine in boosting immunity following initial Covishield inoculation. https://jidc.org/index.php/journal/article/view/15368SARS-CoV-2COVID-19heterologous immunizationhumoral immunityvaccinesneutralizing antibodies |
| spellingShingle | Ali Toloue Ostadgavahi Ryan Booth Gary Sisson Nichole McMullen Michelle Warhuus Peter Robertson Matthew Miller Wanda C Allen May El Sherif Robert Brownlie Darryl Falzarano Christopher D Richardson Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response Journal of Infection in Developing Countries SARS-CoV-2 COVID-19 heterologous immunization humoral immunity vaccines neutralizing antibodies |
| title | Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response |
| title_full | Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response |
| title_fullStr | Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response |
| title_full_unstemmed | Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response |
| title_short | Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response |
| title_sort | heterologous immunization with covishield and pfizer vaccines against sars cov 2 elicits a robust humoral immune response |
| topic | SARS-CoV-2 COVID-19 heterologous immunization humoral immunity vaccines neutralizing antibodies |
| url | https://jidc.org/index.php/journal/article/view/15368 |
| work_keys_str_mv | AT alitoloueostadgavahi heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT ryanbooth heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT garysisson heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT nicholemcmullen heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT michellewarhuus heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT peterrobertson heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT matthewmiller heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT wandacallen heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT mayelsherif heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT robertbrownlie heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT darrylfalzarano heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse AT christopherdrichardson heterologousimmunizationwithcovishieldandpfizervaccinesagainstsarscov2elicitsarobusthumoralimmuneresponse |